Price T Rowe Associates Inc Provention Bio, Inc. Transaction History

Price T Rowe Associates Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$6.7 - $24.21 $40,508 - $146,373	-6,046 Reduced 19.42%	25,091 $605,000
Q4 2022 Feb 14, 2023	BUY	$4.52 - $10.57 $7,132 - $16,679	1,578 Added 5.34%	31,137 $329,000
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.62 $32,279 - $52,889	9,411 Added 46.71%	29,559 $134,000
Q2 2022 Aug 15, 2022	BUY	$3.65 - $7.3 $992 - $1,985	272 Added 1.37%	20,148 $81,000
Q1 2022 May 16, 2022	BUY	$3.4 - $7.88 $67,578 - $156,622	19,876 New	19,876 $145,000
Q3 2021 Nov 15, 2021	SELL	$5.66 - $8.33 $56,956 - $83,824	-10,063 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$6.71 - $11.04 $67,522 - $111,095	10,063 New	10,063 $85,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.